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Summary 
The human neocortex differs from that of other great apes in several notable regards 
including altered cell cycle, prolonged corticogenesis, and increased size [1-5]. While 
these evolutionary changes likely contributed to the origin of distinctively human cognitive 
faculties, their genetic basis remains almost entirely unknown. Highly conserved non-
coding regions showing rapid sequence changes along the human lineage are candidate 
loci for the development and evolution of uniquely human traits.  Several studies have 
identified human-accelerated enhancers [6-14], but none have linked an expression 
difference to a specific organismal trait. Here we report the discovery of a human-
accelerated regulatory enhancer (HARE5) of FZD8, a receptor of the Wnt pathway 
implicated in brain development and size [15, 16]. Using transgenic mice, we demonstrate 
dramatic differences in human and chimpanzee HARE5 activity, with human HARE5 
driving early and robust expression at the onset of corticogenesis. Similar to HARE5 
activity, FZD8 is expressed in neural progenitors of the developing neocortex [17-19]. 
Chromosome conformation capture assays reveal HARE5 physically and specifically 
contacts the core Fzd8 promoter in the mouse embryonic neocortex. To assess the 
phenotypic consequences of HARE5 activity, we generated transgenic mice in which 
Fzd8 expression is under control of orthologous enhancers (Pt-HARE5::Fzd8 and Hs-
HARE5::Fzd8). In comparison to Pt-HARE5::Fzd8, Hs-HARE5::Fzd8 mice showed 
marked acceleration of neural progenitor cell cycle and increased brain size. Changes in 
HARE5 function unique to humans thus alter cell cycle dynamics of a critical population 
of stem cells during corticogenesis, and may underlie some distinctive anatomical 
features of the human brain.  
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Results 
Identification of human-accelerated enhancer loci in the developing neocortex 
The dramatic expansion of the neocortex during hominoid evolution is proposed to 
underlie the emergence of our uniquely human cognitive abilities [20-22], although strong 
genetic correlations between these traits have remained elusive [23]. The evolution of 
human cortical features, such as enlarged brain size, has been attributed to cellular 
changes including neuron number and neural progenitor cell cycle [1-5, 15]. However the 
genetic basis for these traits, which so markedly distinguish humans from other primates, 
remains poorly understood. Mutations within regulatory elements have been proposed to 
play a significant role in the evolution of human-specific traits [24, 25]. Recent genomic 
studies support this notion, and have collectively identified highly conserved non-coding 
regions that are rapidly evolving along the human lineage [6-10]. Of note, these human-
accelerated noncoding loci are frequently located nearby genes implicated in brain 
development and function [11, 26, 27]. Together, these studies suggest the evolution of 
human neocortical traits may have occurred through modification of cis-regulatory 
enhancers involved in brain development. Yet to date just a handful of human-accelerated 
regions have been shown to function as forebrain enhancers [11-13] and none have been 
shown to impact neocortical expansion. Here we sought to discover human-accelerated 
regulatory loci important for corticogenesis, in order to gain insights into the genetic basis 
for the evolution of uniquely human brain features. 
We identified HARE5 from an in silico screen for rapidly evolving human noncoding 
regions predicted to function as developmental enhancers in the mammalian neocortex 
(Figure S1A, Table S1, Supplemental Experimental Procedures)[6-8, 28, 29]. Using a 
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standard mouse transient transgenic assay [11, 14], HARE5 reporter activity was robust 
in the lateral neocortex and dorso-lateral midbrain (15/15 embryos) (Figures 1A, S1C). 
HARE5 was prioritized due to this enhancer activity and its chromosomal location 
adjacent to FRIZZLED8 (FZD8), a receptor for the Wnt signaling pathway implicated in 
neocortical development (Figure 1B)[15-18, 30, 31]. The Homo sapiens (Hs) HARE5 
orthologue contains 16 changes compared to Pan troglodytes (Pt). Based on outgroup 
comparison, 10 mutations were fixed on the human branch and 6 on the chimpanzee 
branch since the latest common ancestor (Figure 1B).  A phylogenetic analysis of the 1.2 
Kb HARE5 locus across several great ape species revealed a longer branch for the Hs 
orthologue compared to that of Pt (Figure 1C). This is consistent with the original 
signature of positive selection detected in the human relative to chimpanzee lineage [7]. 
Analysis of predicted transcription factor binding sites across the HARE5 locus revealed 
differences, particularly at human-derived mutations, for key transcription factors relevant 
to corticogenesis (see Table S2) [32]. Together these results support the prediction that 
Hs-HARE5 acquired unique enhancer activity since diverging from the common 
chimpanzee lineage.  
 
Distinct enhancer activity of human and chimpanzee HARE5 in the developing 
neocortex 
We postulated that human and chimpanzee HARE5 might differentially regulate gene 
expression during corticogenesis. To test this we generated independent stable mouse 
transgenic lines (Pt-HARE5::LacZ and Hs-HARE5::LacZ). Corticogenesis initiates at 
embryonic day (E) 9.5 and continues to E18.5 [2]. At E9.5, both Pt-HARE5 and Hs-
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HARE5 enhancer activity were undetectable (Figures 2A-C). However within a half day 
of development at E10.0, Hs-HARE5 activity was rapidly and robustly upregulated in the 
lateral telencephalon (Figures 2E,F). In contrast, Pt-HARE5 activity in the E10.0 
telencephalon was markedly weaker and limited to more lateral regions (Figures 2D,F). 
This spatial difference in enhancer activity was sustained at E10.5, as evidenced by both 
whole mount embryos and coronal brain sections (Figures 2G-I, S2A-D). By E11.5, 
species-specific differences in HARE5-driven LacZ activity were still evident, although far 
less dramatic (Figures 2J-L). These results indicate that HARE5 orthologues drive 
expression in the developing lateral telencephalon. However, relative to chimpanzee, the 
human enhancer has considerably earlier and robust activity during corticogenesis.  
Having established spatial and temporal differences in chimpanzee and human 
HARE5 enhancer activity, we next sought a more sensitive and dynamic readout of 
HARE5 transcriptional activity. The LacZ protein is stable for at least 48 hours whereas 
destabilized fluorescent proteins with PEST motifs are only stable for 2 hours post-
translation [33]. We generated new stable transgenic mouse lines, Pt-
HARE5::tdTomatoPEST and Hs-HARE5::EGFP-PEST, and  compared native 
fluorescence in embryos co-expressing the reporters (Figures 2M,N). Both orthologues 
drove enhancer activity in the E11.0 neocortex, however Hs-HARE::EGFP was 
considerably brighter than Pt-HARE5::tdTomato, despite tdTomato having intrinsically 
brighter fluorescent emission than EGFP (Figures 2N-T) [33]. This reporter difference was 
sustained at E12.5, though the chimpanzee enhancer remained active (Figures 2U-AA, 
S2E-H). We quantified enhancer activity by RT-qPCR measurement of reporter transcript 
levels in E12.5 neocortices. Hs-HARE5::EGFP embryos showed 10-30 fold higher 
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transcript levels than Pt-HARE5::tdTomato (Figure 2BB). Hence multiple independent 
reporter lines (LacZ and fluorescent) demonstrate that compared to chimpanzee HARE5, 
human HARE5 drives dramatically higher enhancer activity in the telencephalon.  
In the E10.5 telencephalon, the predominant neural progenitor populations are 
neuroepithelial cells, and by E12.5 these are replaced by radial glia (termed neural stem 
cells) [2]. At E10.5, both enhancers were active in the majority (about 75%) of Pax6-
positive neuroepithelial cells and in some TuJ1-positive neurons (Figures S3I-U). At 
E12.5, reporter activity was highest in the ventricular zone (VZ) (Figure 2SE-H), where 
radial glial cells reside. Thus both human and chimpanzee HARE5 enhancers are active 
in neural progenitors of the developing neocortex. 
 
Chromosome conformation capture (3C) detects HARE5-Fzd8 interactions 
Having established HARE5 activity within the lateral telencephalon, we next sought to 
identify the likely target gene. The most proximal gene, Hs-FZD8, is located 307,758 bps 
downstream from HARE5 and was an obvious candidate due to its expression in the 
developing human and mouse neocortex [17-19, 30, 31]. LacZ reporter activity and Fzd8 
in situ hybridization showed similar expression patterns in E10.5 and E11.5 whole mount 
embryos and neocortical sections (Figure S3)(developingmouse.brain-map.org and 
www.emouseatlas.org) [31]. We used chromosome conformation capture (3C) assays 
[34] to test for physical association between endogenous mouse (Mm) HARE5 and the 
core Fzd8 promoter within E12.5 mouse neocortices (Figure 3A). In neocortices we 
observed a strong peak of interaction between Mm-HARE5 and the proximal Fzd8 
promoter, compared to flanking loci (Figure 3B). In contrast, no interactions were evident 
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between Mm-HARE5 and Fzd8 in age-matched liver, which lacks detectable HARE5 
activity and Fzd8 expression. These data indicate HARE5 physically and specifically 
associates with the core Fzd8 promoter in the developing mouse neocortex. Given the 
cis-regulatory activity of HARE5 orthologues, we propose HARE5 functions as a distal-
acting enhancer of FZD8 during early human neocortical development.  
 
Human HARE5 accelerates neural progenitor cell cycle and impacts neocortical 
size 
We next assessed the functional consequences of chimpanzee and human HARE5 
activities during corticogenesis. We generated new independent transgenic mouse lines 
in which Hs-HARE5 or Pt-HARE5 drove expression of a MYC-tagged mouse Fzd8 coding 
sequence (Pt-HARE5::Fzd8 and Hs-HARE5::Fzd8) (Figure 4A). Expression of MYC in 
embryonic neocortices was confirmed by western blot analysis (Figure S4A). We 
postulated that Fzd8 expression driven by the HARE5 enhancer would impact the cell 
cycle state of neural progenitors based upon the following rationale. First, both Hs-HARE5 
and Pt-HARE5 drive expression in neural progenitors. Second, modulating Fzd8 levels 
impacts neural progenitor cell cycle in the retina [18]. Third, overexpression of stabilized 
-catenin, a Wnt signaling component downstream of Frizzled, induces an expanded and 
gyrencephalic brain and slows cell cycle exit of neural stem cells in mice [15]. Fourth, cell 
cycle length is critical for corticogenesis and is postulated as a likely mechanism for the 
evolutionary expansion of the primate neocortex [35, 36].  
We measured the cell cycle state of progenitors at E12.5, predicting that species-
specific differences in HARE5 activity would be evident within two days of onset of 
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enhancer activity. At this stage, radial glial progenitors primarily undergo symmetric 
divisions to expand laterally, but a subset divides asymmetrically to produce excitatory 
neurons [2]. Quantification of G2/M phases using phospho-histoneH3 (PH3) staining 
revealed a significant 1.3-fold increase in the proportion of total PH3+ cells in Hs-
HARE5::Fzd8 brains relative to both Pt-HARE5::Fzd8 and non-transgenic wild-type (WT) 
littermates (Figures 4B-E). We also observed a trend towards more Pax6-positive radial 
glia in Hs-HARE5::Fzd8 brains, with a significant increase relative to WT (Figure S4B). 
These snapshot measurements indicate that at E12.5 Hs-HARE5 driven expression of 
Fzd8 alters the proliferating population. More G2/M positive progenitors may indicate a 
faster overall cell cycle with similar G2/M phases, or alternatively an identical cell cycle 
with longer G2/M.   
To help discriminate between these possibilities, we quantified cell cycle duration at 
E12.5. We used a paradigm of 2 hour BrdU exposure and 30 minute EdU exposure 
coupled with Ki67 staining, as previously described [37] (Figures 4F). Both WT and Pt-
HARE5::Fzd8 progenitors cycled for about 12 hours, as previously reported for this age 
[37, 38]. In contrast Hs-HARE5 driven Fzd8 expression significantly accelerated both the 
total cell cycle (to approximately 9.2 hours) and S phase, by 25% (Figures 4G-J, Table 
S3). These cell cycle differences correspond to a 23% shorter G1/G2/M duration (Tc-Ts) 
of Hs-HARE5::Fzd8 progenitors compared to Pt-HARE5::Fzd8 (P=0.003). Taken together, 
this functional analysis reveals that relative to both WT and Pt-HARE5::Fzd8, human 
HARE5 directed expression of Fzd8 accelerates neural progenitor cell cycle.  
Increased proliferation of neural progenitors is frequently associated with changes in 
brain size. Therefore, we measured the cortical dimensions of transgenic E18.5 brains. 
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Compared to Pt-HARE5::Fzd8 and WT, the dorsal area of Hs-HARE5::Fzd8 cortices was 
significantly larger by 12% (Figures 4K-O). Across 5 additional measurements, Hs-
HARE5::Fzd8 cortices were consistently larger than both Pt-HARE5::Fzd8 and WT 
(Figures S4F-H). As larger cortical area could be due to increased cortical thickness or 
tangential length, we quantified these dimensions in sagittal and coronal sections (Figures 
4P-S). Hs-HARE5::Fzd8 brains were thinner than Pt-HARE5::Fzd8 and WT, although 
differences were only significant in comparison to WT (Figure S4I). In contrast, compared 
to both Pt-HARE5::Fzd8 and WT, Hs-HARE5::Fzd8 brains showed significantly longer 
tangential distance along the cortical VZ (Figure 4S). As seen in other mutants with longer 
tangential growth, Hs-HARE5::Fzd8 brains also showed enlarged ventricles. The 
increased tangential length phenotype is often associated with greater progenitor 
proliferation and larger cortical size, as evidenced in mouse embryonic brains mis-
expressing -catenin or FGF2 [15, 39]. These data indicate that tangential expansion is 
a likely contributing factor for the increased cortical area. 
We predicted faster progenitor proliferation would ultimately be associated with more 
neurons. To test this, we quantified the densities of FoxP1-positive neurons (mid-layers 
III-V), born between E13.5-E16.5, and FoxP2 neurons (deep-layer VI), born around E12.5 
(Figures 4T-AA) within radial columns of E18.5 brains [40, 41].  Compared to chimpanzee, 
Hs-HARE5::Fzd8 brains showed a significant 14% increase in the density of FoxP1 
neurons, but no difference in FoxP2 neurons, nor any notable apoptosis. Thus, Hs-
HARE5::Fzd8 brains contain a higher density of neurons that are produced beginning 
around E13.5. Together these data indicate that, compared to Pt-HARE5, Hs-HARE5 
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promotes faster progenitor cell cycle, which is ultimately associated with increased Foxp1 
excitatory neuron density, and overall larger cortical size.  
 
Discussion 
The neocortex expanded spectacularly during human evolution, giving rise to distinctively 
human anatomical and cognitive capabilities [1, 2, 20-22]. Yet to date, just a handful of 
genetic loci have been associated with human-specific brain traits [3, 5, 25], and none 
have been shown to functionally impact corticogenesis in an evolutionarily divergent 
fashion. In this study we report the discovery of the first human-accelerated enhancer that 
functions in brain development. We demonstrate dramatic temporal and spatial 
differences in activity of human and chimpanzee enhancers of FZD8 during early 
corticogenesis, and show these differences impact neural progenitor cell cycle and brain 
size. Our study suggests the intriguing hypothesis that evolutionary changes in HARE5 
sequence and activity contributed to the origin of unique features of the human brain. 
The evolutionarily divergent activities of HARE5 support a model proposed 16 years 
ago by Pasko Rakic, that species differences in progenitor proliferation may contribute to 
distinctions in brain size between humans and non-human primates. The proposed radial 
unit hypothesis predicts that the number and proliferative capacity of progenitor cells 
drives the evolution of brain cytoarchitecture and explains species differences in 
neocortical size and structure [36].  Indeed both empirical and predicted measurements 
of neural progenitor cell cycle reveal stark differences between humans, non-human 
primates, and mice [1, 36, 42]. In non-human primates, distinct G1 phase durations are 
 11 
associated with unique brain cytoarchitecture [35]. Moreover genetic evidence strongly 
supports a causal link between neural stem cell proliferation and human brain size [43].  
How might a faster cell cycle impact human brain size?  We speculate that in the 
context of extended human corticogenesis and gestation, HARE5 increases progenitor 
proliferation, which expands the progenitor pool during early corticogenesis. Increased 
progenitor expansion would ultimately produce more neurons and a larger neocortex. 
This could involve either altering progenitor cell cycle exit and/or the division state of 
progenitors from neurogenic to proliferative. In E14.5 mice, proliferating and neurogenic 
neural progenitors have distinct S phase durations [44]. Experimentally shortening G1 
phase in mice promotes proliferative divisions in lieu of neurogenic divisions, impacting 
neuron production [45, 46]. Our study implicates shorter G1 as a potential mechanism, 
as the Tc-Ts fraction was shorter in human transgenic brains. Follow-up studies of the 
Hs-HARE5::Fzd8 mouse will clarify the detailed relationship between altered cell cycle 
and brain size, and elucidate if modifications in structural and behavioral traits exist. 
We have shown that a key target gene of HARE5 activity in the neocortex is FZD8, 
which encodes a Wnt receptor. Given the neurogenesis roles of -catenin and Lef/Tcf, it 
is likely that FZD8 acts via canonical Wnt signaling [16]. FZD8 expression in the neonatal 
human brain is highest in cortical areas at 9 pcw (post conception weeks) 
(brainspan.org)[19] when neural stem cells are rapidly expanding during early 
corticogenesis [2], but markedly lower in non-cortical areas. The FZD8 expression pattern 
correlates strongly with neural stem cell markers SOX2 and PAX6 (r > 0.90)[19, 47]. 
Hence the pattern of HARE5 activity and FZD8 expression is consistent with a functional 
relationship in neural stem cell regulation in humans. Although chimpanzee expression 
 12 
data are not available, developing rhesus macaque (Macaca mulatta) neocortical data 
are (www.blueprintnhpatlas.org). Relative to 10 common transcripts of human and 
macaque developing neocortices, FZD8 was more abundant in humans. As RNA 
expression data becomes available [48], it may become possible to more directly 
compare FZD8 levels in human and non-human primates.  
In addition to its requirement for early mouse corticogenesis, Wnt signaling is 
implicated in human brain traits. In 2002 Chenn et al. showed that expression of stabilized 
-catenin induced a larger, gyrencephalic phenotype reminiscent of the human brain [15]. 
However, evidence for the involvement of this pathway in human brain evolution has 
remained elusive until now. Our identification of HARE5 highlights the transcriptional 
regulation of Wnt signaling components as a new avenue to explore for understanding 
the evolutionary origin of human specific anatomical and cognitive traits. With the ability 
to identify regulatory elements active during development [49], we are now poised for the 
discovery of additional loci and pathways whose modification provided the underpinnings 
for the evolution of the human brain.  
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Figure Legends 
Figure 1. Identification of Hs-HARE5 as a human-accelerated neocortical enhancer. 
(A) Representative E14.5 Hs-HARE5::LacZ embryo stained for-galactosidase (LacZ) 
activity. (B) Schematic of Hs-HARE5 locus on human chromosome 10 (hg19). The 1,219 
bp long HARE5 genomic locus with enhancer activity includes the original 619 bp human-
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accelerated sequence and flanking 5’ and 3’ sequences. Represented below is a 
PhastCons conservation track for the HARE5 locus, shown with the region of high 
conservation (grey).  Also shown are lineage-specific mutations for chimpanzee (6, 
arrows, above line), and human (10, arrowheads, bottom), including 1 Denisovan (red) 
and 1 currently identified human polymorphism (blue). (C) Maximum likelihood 
phylogenetic tree for the HARE5 orthologous locus from five anthropoid primates. Scale 
bars, 2 mm (A). See also Figure S1 and Table S1. 
 
Figure 2. Hs-HARE5 activity drives robust, early enhancer activity relative to Pt-
HARE5 during corticogenesis. (A-L) Developmental time-series of Pt-HARE5::LacZ 
(A,D,G,J) and Hs-HARE5::LacZ (B,E,H,K) reporter activity from stable transgenic lines. 
Representative images of LacZ stained embryos from lateral (top) and anterior (bottom) 
views. (C,F,I,L) Enhancer activity was qualitatively scored in the telencephalon, using the 
indicated scoring schema shown on the right, on a scale from no reporter activity (score 
0) to full telencephalic activity (score 5). Number of embryos and independent transgenic 
lines analyzed for each stage are listed below. Embryos were scored blindly and 
independently by at least three individuals. (M) Schematic of destabilized reporter 
constructs drawn to scale. (N-AA) Representative embryos from dual reporter transgenic 
Pt-HARE5::tdTomato; Hs-HARE5::EGFP E11.0 (N-T) and E12.5 (U-AA) embryos 
detected by brightfield (N,U), and endogenous fluorescence for tdTomato (O,Q,S,V,X,Z) 
and EGFP (P,R,T,W,Y,AA) channels. Dotted lines demarcate dorsal neocortices of whole 
mount embryos (N-P, U-W). (Q,R,X,Y) Coronal sections from mid-cortex (plane indicated 
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by arrowhead in N,U) in tdTomato (Q,X) and EGFP (R,Y) channels. (S,T,Z,AA) High-
magnification images of the lateral telencephalon for tdTomato (S,Z) and EGFP (T,AA). 
The number of embryos and lines for each analysis is listed beside U. Endogenous 
fluorescence images were captured using identical exposure conditions. (BB) Graph 
depicting log fold changes for RT-qPCR from E12.5 neocortices. Each data point is the 
average fold change for an individual Hs-HARE5::EGFP embryo relative to the 
aggregated average for all Pt-HARE5::tdTomato embryos. mRNA input levels were 
normalized to Gapdh. n=4 technical replicates per embryo; n=9 embryos from 3 
transgenic lines from each genotype. Scale bars, 1 mm (A-K), 500 m (N-P, U-W); 150 
m (Q,R,X,Y);  25 m (S,T,Z,AA). See also Figure S2 and Table S2. 
 
Figure 3. 3C analysis showing HARE5 physically contacts the Fzd8 promoter.  (A) 
Schematic of 3C protocol showing HARE5 and Fzd8 loci (black bars), with indicated 
TaqMan probe (blue bar), test primers (black half arrows), and HindIII restriction sites (red 
lines). (B) 3C assay of E12.5 mouse neocortices (blue dots) and liver control tissue (red 
dots). Dark vertical line indicates location of TaqMan probe and constant primer anchored 
within the Mm-HARE5 locus. The 0 position indicates ATG of Fzd8 coding sequence. The 
graph depicts the relative frequency of interactions between Mm-HARE5 and 6 genomic 
locations. See also Figure S3. 
 
Figure 4. Hs-HARE5 driven expression of Fzd8 accelerates cell cycle of neural 
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progenitors, and increases neuron number and neocortical size. (A) Schematic of 
Pt-HARE5::Fzd8 and Hs-HARE5::Fzd8 constructs. (B-I) Images of coronal sections from 
E12.5 WT littermate (B,G), Pt-HARE::Fzd8 (C,H), and Hs-HARE5::Fzd8 (D,I) transgenic 
cortices. Sections stained for (B-D) PH3 (green) and Hoechst (blue), (G-I) BrdU (green) 
and EdU (red). (E) Graph of WT (white), Pt-HARE::Fzd8 (grey), and Hs-HARE5::Fzd8 
(black) depicting percentage of all cells that are PH3-positive. (F) Paradigm for analysis 
of cell cycle length using double pulse of BrdU and EdU. Nucleotide analogs were injected 
at indicated time-points and overall cell cycle length (Tc) and S phase length (Ts) were 
calculated as shown. (J) Graph of WT (white), Pt-HARE::Fzd8 (grey), and  Hs-
HARE5::Fzd8 (black) cell cycle lengths of cycling progenitors. (K-M) Whole mount E18.5 
brains from indicated genotypes with n=number of brains examined. A dotted line was 
drawn on WT cortex in K to indicate dorsal cortical area, and then superimposed on 
transgenic cortices in L and M. (N) Schematic cartoon representation of E18.5 brain with 
indicated regions of analyses for sagittal sections (P-S) and coronal sections (T-AA). (O) 
Graph of WT (white), Pt-HARE::Fzd8 (grey), and  Hs-HARE5::Fzd8 (black) dorsal cortical 
area measurements. Note a 12% increase was seen in Hs-HARE5::Fzd8 cortical area. 
(P-R) Sagittal E18.5 sections from brains of indicated genotypes. A line drawn on WT 
cortex in P indicates ventricular length, and was superimposed on transgenic cortices in 
Q and R. Note no evidence of cortical gyrification was seen. (S) Graph depicting 
ventricular length for indicated genotypes. (T-V, X-Z) Coronal E18.5 sections from 
neocortices of indicated genotypes and stained for Foxp1  (T-V) and Foxp2 (X-Z). Note 
no significant apoptosis was observed.  (W, AA) Graphs depicting densities of Foxp1 (W) 
and Foxp2 (AA) neurons in radial columns of neocortical sections. The following were 
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analyzed for each genotype: for B-E, n=5 embryos each from 3 transgenic lines; for F-J, 
5-7 embryos each from 2-3 transgenic lines; K-O, 16-57 embryos each from 2-3 
transgenic lines; P-S, 4-5 embryos each (2-5 sections per embryo) from 2-3 transgenic 
lines; T-AA, 5-6 embryos each (2-4 sections per embryo) from 2-3 transgenic lines. All 
analyses were done blind to genotype. Error bars, s.d., *, P < 0.05, **, P<0.01, ***, 
P<0.001. Scale bars, 25 m (B-I), 1 mm (K-M), 500 m (P-R), and 100 m (T-Z). See 









Figure S1, Related to Figure 1. Screen for evolutionarily important enhancers. (A) 
Schematic workflow for identifying human-accelerated brain enhancers, as described in 
Supplemental Experimental Procedures. 106 unique putative neocortical enhancer loci 
with signatures of positive selection were identified from the screen (see also Table S1).  
(B) Images of E14.5 representative transient transgenic embryos for HARE1-6 assayed 
for β-galactosidase activity, and listed with relevant information. HARE1-6 were prioritized 
from the screen based on their proximity to genes known or predicted to be involved in 
corticogenesis. Selection scans are from following references (first author name listed): 
human-accelerated conserved noncoding sequence [S1]; accelerated conserved 
noncoding sequence [S2]; and primate accelerated region [S3]. Chip-Seq are from the 
following references: H3K4me1 [S4], P300 [S5]. HAREs1, 2, and 4 showed variable 
enhancer activity, whereas HAREs 3, 5, and 6 demonstrated more consistent LacZ 
enhancer activity. C) Images of E14.5 transient transgenic embryos for Hs-HARE5::LacZ 
assayed for β-galactosidase activity. Note HARE5 activity in the lateral forebrain and 
dorso-lateral midbrain, and to a lesser and more variable extent in the spinal cord and 
retina. Scale bars, 2mm.  
  
Figure S2, Related to Figure 2. HARE5 activity in the lateral telencephalon. (A-C) 
Rostral to caudal coronal sections from E10.5 Hs-HARE5::LacZ brains depicting LacZ 
activity in the lateral telencephalon with a graded dorso-ventral boundary. (D) Comparison 
of rostro-caudal matched coronal sections from Hs-HARE5::LacZ  and Pt-HARE5::LacZ 
E10.5 embryos. Arrows indicate boundary of uniform LacZ activity and arrowheads 
indicate boundary of graded LacZ activity. (E-H) Immunofluorescence of E12.5 coronal 
sections co-expressing Pt-HARE5::tdTomato and Hs-HARE5::EGFP at low magnification 
(E,F) and high-magnification along the lateral wall (G,H), and stained with anti-RFP (E, 
G) and anti-EGFP (F,H).  Note both reporters are active in the VZ/SVZ of the lateral 
telencephalon. (I-U) Immunofluorescence of E10.5 coronal sections co-expressing Pt-
HARE5::tdTomato (I-K; P-R) and Hs-HARE5::EGFP (L-N; S-U) and stained with anti-RFP 
(I,P), anti-EGFP (L,S), anti-Pax6 (J,K,M,N) or anti-TuJ1 (Q,R,T,U).  Note, Hs-HARE5 and 
Pt-HARE5 activity are high in Pax6-positive neuroepithelial cells but are also evident in 
some TuJ1-positive neurons.  (O) Graph depicting fraction of all Pax6-positive cells that 
co-stain for either RFP (Pt) or EGFP (Hs). Note td-Tomato was recognized by anti-RFP.  
Error bars, s.d. ns, not significant. Scale bars, 100 m (A-F), 20 m (G,H), 25 m (I-N, P-
U). 
 Figure S3, Related to Figure 3. Hs-HARE5 activity and mouse Fzd8 mRNA 
expression. (A-E) E10.5 whole mount lateral views (A,B) and E11.5 sagittal sections (C-
E) from Hs-HARE5::LacZ embryo stained for LacZ activity (A,C,E) or for in situ 
hybridization of mouse Fzd8 mRNA (B,D). In situ images are from www.emouseatlas.org 
[S6] (B), and http://developingmouse.brain-map.org (D). Note Hs-HARE5 and Mm-
HARE5 share 51.1% sequence identity, as typical for highly conserved noncoding loci 
[S2, S3].  (E) High magnification image of Hs-HARE5::LacZ stained section in C. Scale 
bars, 1 mm (A-D) 590 m (E).  
 Figure S4, Related to Figure 4. Analysis of Pt-HARE5::Fzd8 and Hs-HARE5::Fzd8 
brains. (A) Representative western blot of cortices from Pt-HARE5::Fzd8 and its control 
littermate (E11.5) and Hs-HARE5::Fzd8 and its control littermate (E12.5).  A 10% SDS-
PAGE gel was probed for anti-MYC and anti-Actin, for a loading control. Note a major 
band of 75KDa evident in both transgenic samples but not in control samples. No 
significant difference in MYC levels was detected amongst various samples in replicate 
westerns. (B) Graph depicting quantification of Pax6-positive cells in control (white box), 
Pt-HARE5::Fzd8 (gray box), and Hs-HARE5::Fzd8 (black box) brains. (C-E) Coronal 
E12.5 sections stained for Ki67.  (F) Cartoon representation of E18.5 brains with indicated 
measurements for G,H shown.  (G,H) Graphs depicting measurements of E18.5 whole 
mount brains of indicated genotypes. Note Hs-HARE5::Fzd8 cortices trended to be larger 
across all measurements, with significance indicated. Included in the bars are the fold 
increases above WT levels.  (I) Graph depicting measurement of coronal sections from 
E18.5 neocortices of indicated genotypes. Scale bars, C-E, 25 m. Error bars, s.d., *, P 
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Table S1. Identification of human/primate-accelerated loci with enhancer marks 
from in silico screen.  Related to Figure 1. 
 
Table S2. Transcription factor prediction analysis.  Related to Figure 2. 
Hs-HARE5 gained binding sites for myc (#1,8,15), a positive regulator of neural stem cell 
proliferation [S7], and lost binding sites for myc repressors (#8,15), including 2 human-
derived and 1 chimpanzee-derived mutations.  Hs-HARE5 lost binding sites for Lef/Tcf 
(#1,9), which mediates repressor activity in the absence of Wnt signaling, both in human-
derived mutations [S8]. 
 
 
Genotype Tc (hr) Ts (hr) Tc-Ts (hr) 
WT 12.01 + 0.73 6.23 + 0.29 5.78 + 0.83 
Pt 12.15 + 1.14 6.34 + 0.96 5.81 + 0.65 
Hs 9.15 + 0.88 4.61 + 0.41 4.45 + 0.65 
P-value Hs vs WT 1.5x10-4 2x10-5 0.016 
P-value Hs vs Pt 1.4x10-4 0.001 0.003 
Table S3. Analysis of cell-cycle kinetics in WT and transgenic E12.5 embryos. 
Related to Figure 4. 
 
 
Supplemental Experimental Procedures 
 
Bioinformatics and in silico screen 
We propose the term human-accelerated regulatory element (HARE) to denote loci that 
have been bioinformatically identified as rapidly evolving in humans and empirically 
demonstrated as in vivo enhancers. We identified putative HAREs from an in silico screen 
using the following approach (outlined in Figure S1A). Enhancer candidate loci were 
obtained from publicly available datasets containing empirically identified enhancers. 
These were derived from ChIP-seq studies of mouse embryonic neocortical tissue or 
neural stem cells including: p300 [S5], PAX6 [S9],  SOX2 [S10], H3K4me1 [S11] and 
H3K27ac [S4].  We then identified regions of overlap between these enhancer loci and 
human-accelerated noncoding regions derived from published datasets [S1-3, S12].  All 
human genomic intervals were then converted to hg19 with the Convert Genome 
Coordinates tool (v1.0.3) using default settings. Mouse genomic intervals (mm9) were 
converted to orthologous human coordinates (hg19) with the Extract Pairwise MAF blocks 
tool (1.0.1) using default settings. MAF blocks were then converted to the BED format 
using the Maf to BED tool (v.1.0.0) under default parameters. Intersections between 
human enhancer regions mapped from the mouse genome and human non-coding 
accelerated regions were determined using the Intersect tool (v.1.0.0) with at least a 1 bp 
of overlap. Phylogenetic analysis of the HARE5 locus was performed with MEGA 
(v5.2.1)[13] on orthologous HARE5 loci obtained from the UCSC Genome Browser 
Convert to New Genome tool. We constructed a maximum likelihood tree using the 
Hasegawa-Kishino-Yano model and a gamma distribution of rates among sites with 5 
discrete categories. We utilized the Galaxy Project platform for analyzing genomic 
datasets [S14]. 
 
Sub-cloning of transgenic constructs  
For all reporter constructs, enhancer loci were amplified from human genomic DNA 
(GM12154) and chimpanzee (#5006007) genomic DNA using Phusion High Fidelity 
Polymerase and directionally cloned into the Gateway entry vector pENTR/D-TOPO 
(Invitrogen) following the manufacturer’s recommendations. DNA reporter constructs 
were generated containing the original human-accelerated locus, and flanking 5’ and 3’ 
sequences, which have been shown to have accessory regulatory motifs required for 
enhancer activity [S15-17].  Clones were then subcloned into the minimal promoter 
hsp68::LacZ destination vector (kind gift of Len Pennacchio, Lawrence Berkeley National 
Laboratory). We generated new fluorescent reporter constructs by modifying the minimal 
promoter hsp68::3nls-CFP-PEST vector (generous gift from Jèròme Collignon, Universitè 
Paris-Diderot). The 3xNLS (nuclear localization sequence) was removed by first 
amplifying the CFP gene without the 3xNLS using primers engineered with BamHI 
(including a Kozak sequence and the first 5 codons of CFP) and a BlpI restriction site 
positioned upstream and downstream, respectively, of the reporter gene. The plasmid 
was then digested with BamHI and BlpI restriction enzymes, which removed both the 
3xNLS and CFP reporter, and re-ligated back together with the PCR amplified CFP gene 
lacking the 3xNLS. We subsequently replaced the CFP reporter gene with PCR amplified 
tdTomato and EGFP genes engineered with BamHI and BlpI restriction sites. Enhancer 
loci were subcloned into the multiple cloning site of either hsp68::EGFP-PEST or 
hsp68::tdTomato-PEST. Reporter constructs Hs-HARE5-hsp68::EGFP-PEST (linearized 
with XbaI, XhoI, and SalI-HF) and Pt-HARE5-hsp68::tdTomato-PEST (linearized with 
XhoI, DraIII, and BstB1) were purified by gel electrophoresis. We generated Hs-
HARE5::Fzd8 and Pt-HARE5::Fzd8 constructs by first synthesizing mouse Fzd8 cDNA 
downstream of the proximal promoter region of hsp68 flanked by XhoI and XbaI restriction 
sites (GenScript). This cassette was transferred to pCAG using XhoI/XbaI and Hs/Pt-
HARE5 was subcloned with XhoI and EcoNI. All DNA sequences used for transgenic 
generation were fully sequenced.  
 
Identification of putative transcription factor (TF) binding sites in HARE5  
To identify potential TF binding sites, we used in vitro DNA binding specificity data 
generated using universal protein-binding microarray (PBM) assays [S18]. PBM data can 
be used to derive TF-DNA binding motifs, but in addition it yields measurements of TF 
binding specificity for all possible 8-bp sequences (8-mers), thus providing a more 
comprehensive view of TF binding preferences compared to DNA motifs. The relative 
binding preference of a TF for each 8-mer on universal PBMs is quantified by the PBM 
enrichment score (E-score) [S18, S19] . The E-score is a modified form of the Wilcoxon-
Mann Whitney statistic and ranges from -0.5 (least favored sequence) to +0.5 (most 
favored sequence), with values above 0.35 corresponding, in general, to sequence-
specific DNA binding of the tested TF [S18].  We used 612 uPBM data sets for human 
and mouse TFs from the UniPROBE database and other resources [S20-23].  For each 
PBM data set, we scanned both the human and the chimpanzee enhancers to identify 
putative TF binding sites, defined as sites containing at least two consecutive 8-mers with 
E-score > 0.35, similarly to the procedure used in [S24]. Next, we focused on the specific 
mutations in the HARE5 locus, and we identified TFs for which: 1) a putative binding site 
was predicted in only one of the two lineages, and 2) the difference in E-score between 
the human and the chimpanzee site was at least 0.2. The selected TFs were used in the 
analyses presented in the Table S3. 
 
Mouse genetics and embryonic analysis 
All experiments were performed in agreement with the relevant regulatory standards from 
the Division of Laboratory Animal Resources and IACUC at Duke University School of 
Medicine.  DNA for pronuclear injection was prepared by digesting fully constructs with 
XhoI/XbaI/SalI-HF (NEB) and purified by electrophoresis (QiaEX II, Qiagen). All linearized 
constructs were submitted to the Duke Transgenic Mouse Facility for pronuclear injection 
into 6SJLF1/J strain blastocysts. For the initial screen transient transgenics were tested 
for enhancer activity using a standard enhancer assay for -Galactosidase activity.  This 
approach can capture spatial and temporal differences in enhancer function (see [S25, 
S26] for relevant discussion). For all analyses of HARE5, following pronuclear injection, 
6SJLF1/J founders were backcrossed to B6/J for subsequent analysis and line 
propagation.  The following lines were generated, with number of lines used shown in 
parentheses: Pt-HARE5::LacZ (3), Hs-HARE5::LacZ (4), Pt-HARE5::tdTomatoPEST (3), 
Hs-HARE5::EGFP-PEST (3), Pt-HARE5::Fzd8 (3), and Hs-HARE5::Fzd8  (3).  All 
analyses of enhancer LacZ activity, fluorescence activity, and functional analyses were 
performed blindly with respect to genotype, and by multiple investigators. 
 
Imaging and immunofluorescence staining of transgenics 
LacZ enhancer activity was detected as previously described [S15, S27].  Images of 
whole-mount LacZ or fluorescent embryos were obtained on a Leica M165 FC 
microscope using the Leica Application Suite software package (v.4.1.0). For sectioning 
LacZ embryos, previously fixed embryos were washed in 1X PBS, incubated overnight in 
30% sucrose and then embedded in OCT. For sectioning all other embryos, mouse 
embryos were fixed in 4% paraformaldehyde for 2 hrs. at room temperature or overnight 
at 4oC and washed 3 x 5 min in 1X PBS solution before an overnight incubation with 30% 
sucrose at 4oC prior to OCT embedding. Tissue sections were cut 20 µm thick on a 
cryostat and transferred to Super-Frost Plus slides (Thermo Scientific). Tissue sections 
were permeabilized with 0.25% triton-X100 in PBS, stained in primary antibodies for 2 hr. 
at room temperature or overnight at 4oC as previously described [S28] using the following 
antibodies: mouse anti-TuJ1 (Covance, 1:400), rabbit anti-Pax6 (Millipore, 1:1,000), 
mouse anti-Pax6 (DSHB, 1:64), mouse anti-MYC (Cell Signaling, 1:200), rabbit anti-Ki67 
(Abcam, 1:200), rabbit anti-RFP (Rockland, 1:400), rabbit anti-Foxp1 (Abcam, 1:200), 
rabbit anti-Foxp2 (Abcam, 1:1000), and chicken anti-EGFP (Abcam, 1:200). EdU stained 
sections were obtained using Click-iT EdU Alexa Fluor 594 Imaging Kit (Invitrogen) using 
manufacturer specifications. Fluorescent images were collected on a Zeiss Observer Z1 
microscope using ApoTome optical sectioning. Images of native fluorescent proteins were 
acquired using the Zeiss 43 HE DsRed (Excitation: 545/15) and 38 HE Green Fluorescent 
(Excitation: 470/40) and Leica GFP3 ET (Excitation: 470/40) and DSR ET (Excitation: 
545/30) filter sets.  
 
RT-qPCR Analysis 
RNA was extracted from microdissected E10.5 mouse neocortices stored in TRI reagent 
(Sigma, Cat #T9424) and stored at -80˚C. RNA was extracted according to manufacturer 
recommendations. RNA samples were treated with DNaseI and cDNA was synthesized 
with iScript cDNA Synthesis Kit (Bio-Rad, Cat # 170-8891). qPCR was performed using 
FastStart Universal SYBR Green Master (Rox) (Roche Applied Science Cat # 
04913922001) or Fast SYBR Green Master Mix (Applied Biosystems, Cat # 4385612) 
using cycling conditions recommended by the manufacturer on an ABI StepOnePlus 
Real-Time PCR machine. Primers (see Table S4) for tdTomato and EGFP were designed 
using Primer3 (v.0.4.0) in order to produce similarly sized amplicons under identical 
cycling conditions. Similar amplification efficiencies for both primer sets were obtained.  
 
Chromosomal Confirmation Capture (3C) Analysis 
3C assays were performed as previously described [S29]. Embryonic neocortices and 
reference liver tissues were obtained from pools of 10-16 E12.5 embryos. Neocortical 
dissections included both the dorsal and ventral telencephalon. Tissue samples were 
dissociated in 0.125% collagenase type I shaking for 1-2 hr. at 37˚C and fixed with 2% 
formaldehyde/10%FBS/PBS for 10 min at room temperature. Cell nuclei were prepared 
from aliquots of 10 million cells and stored at -80˚C until chromatin preparation. Cell nuclei 
were digested with HindIII (New England BioLabs) overnight and re-ligated with T4 DNA 
ligase-HC (Promega) for 1-2 days. Control template DNA for quantification of 3C ligation 
products and normalization was generated from HindIII digested and re-ligated BAC DNA 
covering the mouse HARE5 (RP23-137B19; CHORI), mFzd8 (RP23-292B21; CHORI), 
and Ercc3 (RP23-148C24; CHORI) internal control locus. Re-ligation events from 
chromatin and BAC DNA preparations were detected using TaqMan Gene Expression 
Master Mix (Applied Biosystems) and double-dye labeled oligonucleotide probes 
(PrimeTime Integrated DNA Technologies). All reactions were performed in quadruplicate. 
Quantification of ligation events were determined from standard curves of re-ligated BAC 
DNA covering the locus of interest and normalized against the internal control Ercc3 locus. 
Measurements are reported from at least four biological replicates.  
 
Cell cycle analysis and quantitation 
Analysis of cell-cycle kinetics was performed as previously described [S30, S31].  Briefly, 
pregnant dams were injected with BrdU at T=0 (70 g/g of body weight), EdU (10g/g of 
body weight) at T=1.5 hours, and sacrificed at T=2 hrs. Embryos were immediately fixed 
in 4% paraformaldehyde overnight, and embedded in OCT, and then cryosectioned. For 
detection of BrdU, samples were citrate boiled (Vector Laboratories, Cat H-3300) for at 
least 30 min at 98oC and then incubated 2 hrs with rat anti-BrdU (1:200, Abcam) followed 
by addition of secondary anti-rat (1:400, Molecular Probes). Detection of EdU was 
performed after secondary antibody incubation under conditions specified by the 
manufacturer (Life Technologies, Click-iT 594 or 647). Calculation of total cell cycle length 
(Tc) and length of S phase (Ts) were performed as follows: the portion of cells actively in 
the S-phase cells (S cells) was determined from the number of EdU+ cells, the leaving 
fraction (L cells) was determined by the number of BrdU+/EdU- cells, the total number of 
proliferating cells (P cells) was determined by Ki67+ cells (1:100). Quantification of all cell 
cycle parameters were determined with at least 5 nonconsecutive slides stained for each 
marker and were counted blind to genotype using ImageJ software. Quantification of 
Foxp1 and Foxp2 neurons and Pax6 progenitors was performed using radial columns of 
coronal cortical sections counted with Image J software. For E18.5 brains, images of 
E18.5 embryos were captured using a Leica M165 FC microscope with the Leica 
Application Suite software package (v.4.1.0). Quantitation of tangential length (the 
distance between posterior and anterior boundaries of the ventricle in sagittal sections), 
cortical thickness (measured in coronal sections), and whole mount cortical 
measurements were performed using ImageJ (v1.48s). Measurements were made blind 
to genotype. 
 Western blotting 
Cortical protein samples and Western blotting were performed as previously shown, with 
the following exception, per suggestion of Dr. Hiro Matsunami [S28].  In order to resolve 
and have optimal transfer of the membrane protein, gels were transferred overnight in 
cold at 16 volts, and samples in SDS-Page buffer were not boiled but instead warmed at 
room temperature for 2 hours. Blots were probed with mouse anti-Myc (Cell Signaling, 
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